GAGE8 inhibitors are a specialized class of chemical compounds that are designed to specifically target and inhibit the activity of the GAGE8 protein, which belongs to the GAGE (G antigen) family of proteins. These proteins are characterized by their involvement in various cellular functions, including interactions with other proteins and participation in signaling pathways. The precise biological role of GAGE8 is still under investigation, but it is known to be expressed in specific cellular contexts. Inhibitors of GAGE8 are typically small molecules that interact with the protein at critical sites, such as the active site or other regions necessary for its function. By binding to these sites, the inhibitors disrupt the normal activity of GAGE8, preventing it from carrying out its cellular roles. This inhibition can result from direct competition with natural substrates or from allosteric modulation that alters the protein's conformation.
The design and development of GAGE8 inhibitors involve a deep understanding of the protein's structural biology and the key molecular interactions that underlie its activity. Researchers often employ techniques such as high-throughput screening to identify potential inhibitory compounds, followed by detailed structure-activity relationship (SAR) studies to optimize their efficacy and selectivity. The chemical structures of GAGE8 inhibitors are diverse, often featuring specific functional groups that enable strong binding interactions with the protein. These interactions may include hydrogen bonds, hydrophobic contacts, and van der Waals forces that stabilize the inhibitor within the protein's binding pocket. Additionally, achieving selectivity for GAGE8 over other related proteins is a critical aspect of inhibitor design. This selectivity is typically achieved through careful molecular optimization, ensuring that the inhibitor fits precisely within the unique structural features of GAGE8. The resulting inhibitors are valuable tools for probing the biological functions of GAGE8, providing insights into its role in cellular processes and facilitating further biochemical studies.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Influences GAGE8 activity by modulating phosphorylation pathways crucial in cell cycle regulation and cancer progression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Affects GAGE8 activity as a tyrosine kinase inhibitor, impacting signaling pathways in cancer cell proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Alters the mTOR pathway, involved in cell growth, proliferation, and survival, thereby influencing GAGE8. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Impacts GAGE8 activity indirectly through DNA intercalation and inhibition of topoisomerase II, affecting cancer cell growth. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Modulates signaling pathways in cancer cells, particularly in leukemia, affecting GAGE8 activity. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Disrupts microtubule dynamics as a microtubule stabilizer, impacting GAGE8 indirectly and affecting cancer cell division. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Disrupts RNA and DNA synthesis in cancer cells as a pyrimidine analog, influencing GAGE8. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Affects GAGE8 activity by disrupting protein degradation pathways, crucial in cancer cell survival and proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Influences GAGE8 by targeting multiple kinases involved in cancer cell signaling, proliferation, and angiogenesis. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Impacts GAGE8 indirectly by causing DNA crosslinks, affecting cancer cell growth and triggering apoptosis. | ||||||